304 related articles for article (PubMed ID: 17765756)
1. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders.
Foroughi S; Foster B; Kim N; Bernardino LB; Scott LM; Hamilton RG; Metcalfe DD; Mannon PJ; Prussin C
J Allergy Clin Immunol; 2007 Sep; 120(3):594-601. PubMed ID: 17765756
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation.
Macglashan DW; Saini SS
J Allergy Clin Immunol; 2013 Oct; 132(4):906-11.e1-4. PubMed ID: 23791510
[TBL] [Abstract][Full Text] [Related]
3. Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge.
Eckman JA; Sterba PM; Kelly D; Alexander V; Liu MC; Bochner BS; Macglashan DW; Saini SS
J Allergy Clin Immunol; 2010 Apr; 125(4):889-895.e7. PubMed ID: 19962744
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.
Lin H; Boesel KM; Griffith DT; Prussin C; Foster B; Romero FA; Townley R; Casale TB
J Allergy Clin Immunol; 2004 Feb; 113(2):297-302. PubMed ID: 14767445
[TBL] [Abstract][Full Text] [Related]
5. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge.
Ong YE; Menzies-Gow A; Barkans J; Benyahia F; Ou TT; Ying S; Kay AB
J Allergy Clin Immunol; 2005 Sep; 116(3):558-64. PubMed ID: 16159624
[TBL] [Abstract][Full Text] [Related]
6. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal study of the expression of FcεRI and IgE on basophils and dendritic cells in association with basophil function in two patients with severe allergic asthma treated with Omalizumab.
Pereira Santos MC; Campos Melo A; Caetano A; Caiado J; Mendes A; Pereira Barbosa M; Branco Ferreira M
Eur Ann Allergy Clin Immunol; 2015 Mar; 47(2):38-40. PubMed ID: 25781192
[TBL] [Abstract][Full Text] [Related]
8. Effect of omalizumab on biomarkers in middle ear effusion in patients with eosinophilic otitis media.
Iino Y; Hara M; Hasegawa M; Matsuzawa S; Shinnabe A; Kanazawa H; Yoshida N
Acta Otolaryngol; 2014 Apr; 134(4):366-72. PubMed ID: 24628335
[TBL] [Abstract][Full Text] [Related]
9. Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis.
Corren J; Diaz-Sanchez D; Saxon A; Deniz Y; Reimann J; Sinclair D; Davancaze T; Adelman D
Ann Allergy Asthma Immunol; 2004 Sep; 93(3):243-8. PubMed ID: 15478383
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects.
Arm JP; Bottoli I; Skerjanec A; Floch D; Groenewegen A; Maahs S; Owen CE; Jones I; Lowe PJ
Clin Exp Allergy; 2014 Nov; 44(11):1371-85. PubMed ID: 25200415
[TBL] [Abstract][Full Text] [Related]
11. Basophil histamine release decreases during omalizumab therapy in allergic asthmatics.
Noga O; Hanf G; Kunkel G; Kleine-Tebbe J
Int Arch Allergy Immunol; 2008; 146(1):66-70. PubMed ID: 18087163
[TBL] [Abstract][Full Text] [Related]
12. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression.
Prussin C; Griffith DT; Boesel KM; Lin H; Foster B; Casale TB
J Allergy Clin Immunol; 2003 Dec; 112(6):1147-54. PubMed ID: 14657874
[TBL] [Abstract][Full Text] [Related]
13. Effect of omalizumab on peripheral blood eosinophilia in allergic asthma.
Massanari M; Holgate ST; Busse WW; Jimenez P; Kianifard F; Zeldin R
Respir Med; 2010 Feb; 104(2):188-96. PubMed ID: 19846286
[TBL] [Abstract][Full Text] [Related]
14. The effect of omalizumab on nasal allergic inflammation.
Plewako H; Arvidsson M; Petruson K; Oancea I; Holmberg K; Adelroth E; Gustafsson H; Sandström T; Rak S
J Allergy Clin Immunol; 2002 Jul; 110(1):68-71. PubMed ID: 12110823
[TBL] [Abstract][Full Text] [Related]
15. Anti-IgE treatment in allergic rhinitis.
Bayar Muluk N; Bafaqeeh SA; Cingi C
Int J Pediatr Otorhinolaryngol; 2019 Dec; 127():109674. PubMed ID: 31526939
[TBL] [Abstract][Full Text] [Related]
16. Basophil CD203c levels are increased at baseline and can be used to monitor omalizumab treatment in subjects with nut allergy.
Gernez Y; Tirouvanziam R; Yu G; Ghosn EE; Reshamwala N; Nguyen T; Tsai M; Galli SJ; Herzenberg LA; Herzenberg LA; Nadeau KC
Int Arch Allergy Immunol; 2011; 154(4):318-27. PubMed ID: 20975283
[TBL] [Abstract][Full Text] [Related]
17. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding.
Klunker S; Saggar LR; Seyfert-Margolis V; Asare AL; Casale TB; Durham SR; Francis JN;
J Allergy Clin Immunol; 2007 Sep; 120(3):688-95. PubMed ID: 17631952
[TBL] [Abstract][Full Text] [Related]
18. Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy.
Corren J; Shapiro G; Reimann J; Deniz Y; Wong D; Adelman D; Togias A
J Allergy Clin Immunol; 2008 Feb; 121(2):506-11. PubMed ID: 18269927
[TBL] [Abstract][Full Text] [Related]
19. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.
Casale TB; Condemi J; LaForce C; Nayak A; Rowe M; Watrous M; McAlary M; Fowler-Taylor A; Racine A; Gupta N; Fick R; Della Cioppa G;
JAMA; 2001 Dec; 286(23):2956-67. PubMed ID: 11743836
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
